1. Scrip
  2. >>R&D

Plazomicin’s US Debut Pencilled In For 2018, Achaogen Now Searching For Ex-US Partner

 
• By John Davis

Top-line results from the pivotal Phase III EPIC study, and the smaller CARE study in patients with serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) pathogens, should allow Achaogen to find an ex-US marketing partner and submit a US marketing application in 2017 for its potential new antibacterial, plazomicin, that could address a growing market opportunity in multidrug resistant infections.

South San Francisco biotech Achaogen Inc.has announced top-line Phase III results with its lead product, plazomicin, an engineered aminoglycoside, that it says puts it in a position potentially to offer a much needed new treatment option for serious multidrug-resistant bacterial infections.

The company believes plazomicin is unique in the way it has been engineered to make it resistant to aminoglycoside-modifying enzymes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.